NHS, endometriosis and Ryeqo
Relugolix-estradiol-norethisterone (also known as relugolix combination therapy or Ryeqo), is the “first of its kind” daily ...
The new tablet, known as Ryeqo or relugolix-estradiol-norethisterone, has been approved to treat women of reproductive age ...
Ryeqo was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) last October based on results from the LIBERTY programme, consisting of two 24-week phase 3 clinical trials.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results